Most pharma brand teams still picture a WCAG audit as an expert with a checklist, a spreadsheet, and a two-week turnaround. That version of the audit is now the bottleneck. Since 28 June 2025, the European Accessibility Act (Directive EU 2019/882) has been enforceable across all 27 EU member states, and pharmaceutical companies are fully in scope. Patient portals, disease awareness sites, HCP platforms, and mobile health tools all need to conform.
The question is no longer whether to audit. It is how to audit at the speed and depth that the regulation, and your patients, actually require.
This is where AI-assisted auditing changes what a compliance review looks like. Promedia built Audit-Pro as an accessibility skill that reads pharma websites the way different users would, checks every page instead of a sample, and hands designers a prioritised list of fixes grouped by root cause. Here is what that looks like in practice.
A traditional accessibility audit works by extrapolation. An auditor picks 10 to 15 representative pages, tests them against WCAG 2.2 criteria, and assumes the rest of the site behaves similarly. On a 400-page corporate pharma platform with product pages, HCP gated content, patient resources, and campaign microsites, that assumption breaks down quickly.
A modern WCAG audit for a pharma website works differently. It reads the site the way real users would experience it, applying four lenses in parallel:
Each lens surfaces different failures. Audit-Pro applies all four across every page, not a sampled subset. On a recent WCAG 2.1 AA audit report Promedia produced for a multibrand email design system, the scan covered 1,098 nodes in a single pass. That volume is not achievable manually within a reasonable timeline.
The practical workflow has three parts: scan, cluster, prioritise.
The scan captures raw findings against WCAG 2.2 Level AA, which is the standard EN 301 549 aligns with and which the European Accessibility Act references. Automated scanning alone catches roughly 30 to 40% of real accessibility barriers, according to industry testing benchmarks, which is why the second and third steps matter as much as the first.
Clustering is where an AI-assisted audit earns its keep. If one broken button component appears on 80 pages, that is not 80 separate defects. It is one component fix that resolves 80 findings. Audit-Pro groups issues by root cause so your development team sees the underlying problem instead of a flat list of 400 rows. On a design system audit, this often collapses thousands of raw findings into a handful of component-level tickets.
Prioritisation then ranks what remains by real user impact. A decorative image missing alt text is a low-impact finding. A patient support form that cannot be submitted with a screen reader is a blocker. The audit report should tell your team which is which, upfront, so remediation starts where it matters.
WCAG 2.2, published in October 2023, adds nine new success criteria on top of WCAG 2.1. For pharma teams, the most consequential additions cover focus appearance, dragging movements, target size, consistent help, and redundant entry. These matter because patient-facing digital tools often ask users to fill in the same information across multiple steps of a support programme or symptom tracker.
EN 301 549 v4.1.1, which incorporates WCAG 2.2, is expected to become the updated harmonised EU standard for digital accessibility. Pharma sites that only audited against WCAG 2.1 in the past need to close the gap now, particularly on patient information portals and disease awareness platforms where interaction patterns are dense.
Where Audit-Pro helps: it audits against the current WCAG 2.2 criteria across the entire site in hours rather than weeks, which is the difference between running an accessibility review once every 18 months and running it after every sprint.
Once you have a clustered, prioritised report, the sequencing question becomes strategic rather than technical. Three principles hold up well for pharma teams:
The human judgement stays with your team. Audit-Pro handles the volume of the review so your designers, developers, and Medical reviewers can spend their time on decisions, not spreadsheet triage. That division of labour is the point. AI assists the review. Designers decide what to fix. The audit is the foundation, and everything else, from design system remediation to ongoing conformance monitoring, builds on it.
WCAG 2.2 is the current version of the Web Content Accessibility Guidelines, published by the W3C in October 2023. It applies to any pharmaceutical company operating consumer-facing or HCP-facing websites in the EU, because the European Accessibility Act references WCAG-aligned standards through EN 301 549. Patient portals, disease awareness sites, and digital health tools are all in scope.
Automated tools catch roughly 30 to 40% of accessibility barriers, mostly structural issues like missing alt text or contrast failures. Manual testing with assistive technologies is required for the remainder, particularly for workflow-level issues like form completion with a screen reader. AI-assisted audits like Audit-Pro sit between the two: they scale coverage to every page and cluster findings intelligently, while human reviewers validate the highest-impact issues.
If your pharma site has not been audited against WCAG 2.2 in the past 12 months, or if the last audit reviewed a sample rather than the full site, that is the gap worth closing first. A full-site scan with clustered findings gives your team a defensible baseline for the European Accessibility Act and a practical remediation roadmap.
Promedia runs Audit-Pro on pharma websites and design systems as a starting point for accessibility programmes. If you want to see what it finds on your site, that conversation is a short one.
One short email when we publish. No spam, no sales pitch. Unsubscribe whenever.
